• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

September 23, 2019
Company Drug/Device Medical Condition Status
Clover Biopharmaceuticals, Inc. SCB-313 peritoneal carcinomatosis Phase 1 trial initiated enrolling subjects in China
Immunic IMU-935 various inflammatory and autoimmune diseases Phase 1 trial initiated
Benitec Biopharma BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Phase 1 trial initiated
Transgene TG4050 HPV negative, squamous cell carcinoma of the head and neck (SCCHN) Phase 1 trial initiated enrolling subjects that have received an adjuvant (first line) therapy in the UK and France
Transgene TG4050 ovarian cancer Phase 1 trials initiated enrolling subjects after first-line surgery and chemotherapy in France and the U.S.
Poxel SA PXL065 Non-alcoholic steatohepatitis (NASH) Phase 1b trial initiated enrolling 30 healthy subjects
Applied Molecular Transport AMT-101 Ulcerative Colitis Phase 1b trial initiated enrolling 20 adult subjects in Europe
NOXXON NOX-A12 in combination with radiotherapy Brain cancer Phase 1/2 trial recruiting newly diagnosed patients with brain tumors who would not benefit from the current standard of care of chemoradiotherapy and whose tumors cannot be fully resected by surgery in Germany
REVOLUTION Medicines RMC-4630 in combination with cobimetinib (Cotellic) relapsed/refractory solid tumors harboring specific genomic mutations Phase 1b/2 trial initiated
Momotaro-Gene MTG201 in combination with PD-1 inhibitor nivolumab (Opdivo) relapsed malignant pleural mesothelioma Phase 2 trial initiated enrolling 12 subjects with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy at Baylor College of Medicine in Houston, Texas
Pulmatrix Pulmazole Allergic Bronchopulmonary Aspergillosis (ABPA) Phase 2 trial initiated enrolling 64 subjects with asthma
Graybug Vision, Inc. GB-102 macular edema (ME) secondary to Diabetic Macular Edema (DME) or Retinal Vein Occlusion (RVO) Phase 2a trial initiated enrolling 20 subjects at six centers in the U.S.
Alnylam Pharmaceuticals, Inc. patisiran transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy Phase 3 study initiated enrolling 300 adult subjects with ATTR amyloidosis (hereditary or wild type) with cardiomyopathy
Apollo Endosurgery, Inc. Polypropylene Suture-Anchor Assembly pass and anchor suture in the gastrointestinal tract 510(k) Clearance granted by the FDA
Janssen Erleada metastatic castration-sensitive prostate cancer (mCSPC) Supplemental New Drug Application granted by the FDA

Merck

Eisai

Keytruda in combination with Lenvima advanced endometrial carcinoma Approval granted by the FDA
Xeris Pharmaceuticals GVOKE (glucagon) injection severe hypoglycemia Approval granted by the FDA

 

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing